SC
LENZ

Stempoint Capital’s LENZ Therapeutics LENZ Stock Holding History

Stempoint Capital’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-183,912
Closed -$5.39M – 101
2025
Q2 		$5.39M Buy
+183,912
New +$5M 1.73% 22

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stempoint Capital's LENZ Position: Q3 2025 in Review

Stempoint Capital sold out of LENZ Therapeutics (LENZ) in Q3 2025, closing a stake of 183,912 shares — an estimated $5.39M sold.

Stempoint Capital first reported a position in LENZ in Q2 2025 and held it in 1 quarter. The position peaked at $5.39M in Q2 2025. 166 funds tracked by Wall St. Rank hold LENZ as of Q3 2025.

  • Stempoint Capital reported no remaining LENZ Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Stempoint Capital sold 183,912 LENZ Therapeutics shares in Q3 2025, an estimated $5.39M.
  • Stempoint Capital first reported a position in LENZ Therapeutics in Q2 2025 and held it in 1 quarter.
  • Stempoint Capital's LENZ Therapeutics position peaked at $5.39M in Q2 2025.
  • 166 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2025.

Based on Stempoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.